Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTS5K8U)

• DTT Name: P-selectin glycoprotein ligand 1 (SELPLG)
• Synonyms: Selectin P ligand; SPSGL-1; SELPLG; PSGL-1; P-selectin glycoprotein ligand-1; CD162 antigen
• Gene Name: SELPLG
• DTT Type: Clinical trial target; [1]
• UniProt ID: SELPL_HUMAN
• TTD ID: T21865
• Sequence:
  MPLQLLLLLILLGPGNSLQLWDTWADEAEKALGPLLARDRRQATEYEYLDYDFLPETEPP
  EMLRNSTDTTPLTGPGTPESTTVEPAARRSTGLDAGGAVTELTTELANMGNLSTDSAAME
  IQTTQPAATEAQTTQPVPTEAQTTPLAATEAQTTRLTATEAQTTPLAATEAQTTPPAATE
  AQTTQPTGLEAQTTAPAAMEAQTTAPAAMEAQTTPPAAMEAQTTQTTAMEAQTTAPEATE
  AQTTQPTATEAQTTPLAAMEALSTEPSATEALSMEPTTKRGLFIPFSVSSVTHKGIPMAA
  SNLSVNYPVGAPDHISVKQCLLAILILALVATIFFVCTVVLAVRLSRKGHMYPVRNYSPT
  EMVCISSLLPDGGEGPSATANGGLSKAKSPGLTPEPREDREGDDLTLHSFLP
• Function: A SLe(x)-type proteoglycan, which through high affinity, calcium-dependent interactions with E-, P- and L-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation. Critical for the initial leukocyte capture.
• KEGG Pathway:
  Cell adhesion molecules (CAMs) (hsa04514)
  Staphylococcus aureus infection (hsa05150)
• Reactome Pathway: Cell surface interactions at the vascular wall (R-HSA-202733)

Molecular Interaction Atlas (MIA) of This DTT

4 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AbGn-168	DMT6H3J	Allergy	4A80-4A85	Phase 2	[1]
Neihulizumab	DMUPZFO	Psoriatic arthritis	FA21	Phase 2	[2]
RO-4905417	DMV319J	Acute coronary syndrome	BA41	Phase 2	[3]
SelK2	DMM6B6E	Asthma	CA23	Phase 2	[4]

References

• [1] Clinical pipeline report, company report or official report of Avarx.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] WO patent application no. 2013,0144,05, Methods.
• [4] Clinical pipeline report, company report or official report of Tetherex Pharmaceuticals